SIGHT SCIENCES INC (SGHT) Fundamental Analysis & Valuation

NASDAQ:SGHT • US82657M1053

5.41 USD
+0.15 (+2.85%)
At close: Mar 4, 2026
5.15 USD
-0.26 (-4.81%)
After Hours: 3/4/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SGHT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

SGHT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of SGHT is average, but there are quite some concerns on its profitability. SGHT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. SGHT Profitability Analysis

1.1 Basic Checks

  • SGHT had negative earnings in the past year.
  • SGHT had a negative operating cash flow in the past year.
  • SGHT had negative earnings in each of the past 5 years.
  • SGHT had a negative operating cash flow in each of the past 5 years.
SGHT Yearly Net Income VS EBIT VS OCF VS FCFSGHT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • SGHT's Return On Assets of -39.66% is on the low side compared to the rest of the industry. SGHT is outperformed by 63.59% of its industry peers.
  • SGHT has a Return On Equity of -71.72%. This is comparable to the rest of the industry: SGHT outperforms 44.57% of its industry peers.
Industry RankSector Rank
ROA -39.66%
ROE -71.72%
ROIC N/A
ROA(3y)-36.62%
ROA(5y)-36%
ROE(3y)-52.97%
ROE(5y)-61.55%
ROIC(3y)N/A
ROIC(5y)N/A
SGHT Yearly ROA, ROE, ROICSGHT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • Looking at the Gross Margin, with a value of 86.83%, SGHT belongs to the top of the industry, outperforming 96.20% of the companies in the same industry.
  • SGHT's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SGHT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y3.51%
SGHT Yearly Profit, Operating, Gross MarginsSGHT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. SGHT Health Analysis

2.1 Basic Checks

  • SGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SGHT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGHT Yearly Shares OutstandingSGHT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SGHT Yearly Total Debt VS Total AssetsSGHT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • SGHT has an Altman-Z score of -0.85. This is a bad value and indicates that SGHT is not financially healthy and even has some risk of bankruptcy.
  • SGHT has a Altman-Z score of -0.85. This is comparable to the rest of the industry: SGHT outperforms 44.02% of its industry peers.
  • A Debt/Equity ratio of 0.62 indicates that SGHT is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.62, SGHT is doing worse than 65.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -0.85
ROIC/WACCN/A
WACC10.45%
SGHT Yearly LT Debt VS Equity VS FCFSGHT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 9.60 indicates that SGHT has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 9.60, SGHT belongs to the best of the industry, outperforming 90.76% of the companies in the same industry.
  • A Quick Ratio of 8.93 indicates that SGHT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 8.93, SGHT belongs to the top of the industry, outperforming 91.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.6
Quick Ratio 8.93
SGHT Yearly Current Assets VS Current LiabilitesSGHT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SGHT Growth Analysis

3.1 Past

  • SGHT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.18%, which is quite impressive.
EPS 1Y (TTM)27.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.32% on average over the next years. This is quite good.
  • SGHT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.62% yearly.
EPS Next Y18.52%
EPS Next 2Y18.46%
EPS Next 3Y9.32%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y12.94%
Revenue Next 3Y13.62%
Revenue Next 5YN/A

3.3 Evolution

SGHT Yearly Revenue VS EstimatesSGHT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
SGHT Yearly EPS VS EstimatesSGHT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. SGHT Valuation Analysis

4.1 Price/Earnings Ratio

  • SGHT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SGHT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGHT Price Earnings VS Forward Price EarningsSGHT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGHT Per share dataSGHT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.46%
EPS Next 3Y9.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGHT Dividend Analysis

5.1 Amount

  • SGHT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SGHT Fundamentals: All Metrics, Ratios and Statistics

SIGHT SCIENCES INC

NASDAQ:SGHT (3/4/2026, 8:00:03 PM)

After market: 5.15 -0.26 (-4.81%)

5.41

+0.15 (+2.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-04
Earnings (Next)N/A
Inst Owners49.61%
Inst Owner Change12.46%
Ins Owners18.82%
Ins Owner Change2.93%
Market Cap286.03M
Revenue(TTM)N/A
Net Income(TTM)-46.11M
Analysts80
Price Target9.54 (76.34%)
Short Float %2.58%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.11%
Min EPS beat(2)14.4%
Max EPS beat(2)37.82%
EPS beat(4)3
Avg EPS beat(4)11.04%
Min EPS beat(4)-10.81%
Max EPS beat(4)37.82%
EPS beat(8)5
Avg EPS beat(8)9.01%
EPS beat(12)9
Avg EPS beat(12)11.07%
EPS beat(16)11
Avg EPS beat(16)7.09%
Revenue beat(2)2
Avg Revenue beat(2)7.73%
Min Revenue beat(2)5.48%
Max Revenue beat(2)9.98%
Revenue beat(4)3
Avg Revenue beat(4)3.47%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)9.98%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.07%
Revenue beat(16)9
Avg Revenue beat(16)1.15%
PT rev (1m)0%
PT rev (3m)53.7%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)0.42%
EPS NY rev (3m)18.23%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-0.11%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)4.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.76
P/FCF N/A
P/OCF N/A
P/B 4.45
P/tB 4.45
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS1.44
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.66%
ROE -71.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.83%
FCFM N/A
ROA(3y)-36.62%
ROA(5y)-36%
ROE(3y)-52.97%
ROE(5y)-61.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y3.51%
F-Score3
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.15%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.6
Quick Ratio 8.93
Altman-Z -0.85
F-Score3
WACC10.45%
ROIC/WACCN/A
Cap/Depr(3y)106.51%
Cap/Depr(5y)124.16%
Cap/Sales(3y)0.94%
Cap/Sales(5y)1.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.22%
EPS Next Y18.52%
EPS Next 2Y18.46%
EPS Next 3Y9.32%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.9%
Revenue Next Year11.38%
Revenue Next 2Y12.94%
Revenue Next 3Y13.62%
Revenue Next 5YN/A
EBIT growth 1Y9.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.75%
EBIT Next 3Y18.36%
EBIT Next 5YN/A
FCF growth 1Y44.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.27%
OCF growth 3YN/A
OCF growth 5YN/A

SIGHT SCIENCES INC / SGHT FAQ

What is the fundamental rating for SGHT stock?

ChartMill assigns a fundamental rating of 3 / 10 to SGHT.


Can you provide the valuation status for SIGHT SCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to SIGHT SCIENCES INC (SGHT). This can be considered as Overvalued.


Can you provide the profitability details for SIGHT SCIENCES INC?

SIGHT SCIENCES INC (SGHT) has a profitability rating of 2 / 10.


What is the financial health of SIGHT SCIENCES INC (SGHT) stock?

The financial health rating of SIGHT SCIENCES INC (SGHT) is 4 / 10.